| SITE Centers' Q1 OFFO Misses Estimate, Revenues Decline Y/Y |
SITC's first-quarter results reflect a year-over-year fall in revenues and leased rate. |
zacks.com |
2025-05-08 18:40:39 |
Czytaj oryginał (ang.) |
| Sell These 10 REITs While You Still Can |
This neither the best of times nor the worst of times for REIT investors. This article presents a list of 10 REITs that would merit a Sell rating even in the best of times, given their current condition. All 10 REITs face significant risks due to revenue shrinkage, and most are struggling with heavy indebtedness and a high risk of dividend cuts. |
seekingalpha.com |
2025-05-01 10:34:00 |
Czytaj oryginał (ang.) |
| SITE Centers' First Quarter 2025 Earnings to be Released Wednesday, May 7, 2025 |
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers' First Quarter 2025 Earnings to be Released Wednesday, May 7, 2025. |
businesswire.com |
2025-04-30 20:05:00 |
Czytaj oryginał (ang.) |
| Short Interest Down For U.S. REITs In March, Up For Advertising REITs |
Average short interest in US equity real estate investment trusts decreased moderately in March. US REITs' short interest fell 3 basis points month over month to 3.7% of shares outstanding on average in March. The shopping center segment logged the biggest decline in March compared to the previous month, down 1.2 percentage points to 3.3% of shares outstanding on average. |
seekingalpha.com |
2025-04-18 19:02:00 |
Czytaj oryginał (ang.) |
| Should You Retain SITE Centers Stock in Your Portfolio Now? |
SITC is likely to gain from its well-located portfolio, solid tenant roster and capital-recycling moves despite rising e-commerce adoption and elevated interest rates. |
zacks.com |
2025-04-11 16:00:34 |
Czytaj oryginał (ang.) |
| Dividend Power Dogs: 5 Ideal Safe Buys In April |
Five top Dividend Power stocks with "safer" dividends include ZIM Integrated Shipping, FS KKR Capital, Mach Natural Resources, Saratoga Investment, and Golden Ocean. The Dividend Power strategy focuses on high earnings and dividend yields, creating a portfolio resilient in downturns and profitable in bull markets. Analysts project significant gains (49.51% to 140.25%) for the top ten Dividend Power stocks by April 2026, with an average net gain of 92.52%. |
seekingalpha.com |
2025-04-09 08:32:53 |
Czytaj oryginał (ang.) |
| SITE Centers: Cost Control Key After Curbline Properties Spin-Off |
SITE Centers is a retail REIT focused on open-air shopping centers in high-income communities. The REIT's Q4 2024 results show it is slow to adapt general and administrative expenses to a much smaller asset base. I compare SITC's administrative overhead to Simon Property Group, showing room for substantial improvement. |
seekingalpha.com |
2025-03-24 05:35:44 |
Czytaj oryginał (ang.) |
| CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting |
SOUTH SAN FRANSCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it is presenting encouraging preclinical results of lead compound CER-1236 in ovarian cancer during the 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors in San Diego, March 12-14. |
globenewswire.com |
2025-03-13 10:15:00 |
Czytaj oryginał (ang.) |
| Dividend Power Dogs: 3 Top Dividend Picks For March |
Three top Dividend Power stocks, Golden Ocean, Diversified Energy, and Saratoga Investment Corp, offer "safer" dividends with free cash-flow yields exceeding dividend yields. The Dividend Power strategy focuses on high earnings yield and top dividend yield stocks, creating a resilient portfolio for both downturns and bull markets. Analysts predict significant net gains (39.97% to 168.6%) for the top ten Dividend Power stocks by March 2026, with an average net gain of 77.96%. |
seekingalpha.com |
2025-03-12 09:29:29 |
Czytaj oryginał (ang.) |
| Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking place March 12-14, 2025, in San Diego, C.A. Details of the poster presentation are as follows: Abstract Ti. |
businesswire.com |
2025-03-03 09:00:00 |
Czytaj oryginał (ang.) |
| SITE Centers Stock Declines on Q4 OFFO & Revenue Estimate Miss |
SITC's fourth-quarter results reflect a year-over-year fall in revenues and leased rate. |
zacks.com |
2025-02-28 14:50:42 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About SITE Centers Corp. (SITC) Q4 Earnings |
The headline numbers for SITE Centers Corp. (SITC) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-02-27 12:36:04 |
Czytaj oryginał (ang.) |
| Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting |
FRAMINGHAM, MA / ACCESS Newswire / February 27, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting being held March 12 - 14, 2025 in San Diego, CA and virtually. Details for the presentation are as follows: Abstract Number: 123 Title: DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma Presenter: Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute Date & Time: Wednesday, March 12, 2025 at 5:10 p.m. |
accessnewswire.com |
2025-02-27 11:15:00 |
Czytaj oryginał (ang.) |
| SITE CENTERS CORP. (SITC) Misses Q4 FFO and Revenue Estimates |
SITE CENTERS CORP. (SITC) came out with quarterly funds from operations (FFO) of $0.16 per share, missing the Zacks Consensus Estimate of $0.23 per share. |
zacks.com |
2025-02-27 10:40:24 |
Czytaj oryginał (ang.) |
| SITE Centers Reports Fourth Quarter 2024 Results |
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Reports Fourth Quarter 2024 Results. |
businesswire.com |
2025-02-27 08:30:00 |
Czytaj oryginał (ang.) |
| SITE Centers' Fourth Quarter 2024 Earnings to Be Released Thursday, February 27, 2025 |
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers' Fourth Quarter 2024 Earnings to be Released Thursday, February 27, 2025. |
businesswire.com |
2025-02-03 18:05:00 |
Czytaj oryginał (ang.) |
| SITE Centers Announces Tax Allocations of 2024 Dividend Distributions |
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Tax Allocations of 2024 Dividend Distributions. |
businesswire.com |
2025-01-29 18:05:00 |
Czytaj oryginał (ang.) |
| 69 Graham Value All-Stars, Of 20 'Safer' Choices, Buy Any Of 14 |
The Value Score identifies large-cap stocks offering the best value relative to their assets and profits, focusing on low-priced, high-value investments. The Ben Graham Formula targets ultra-stable stocks with strong earnings, dividends, and low valuations, ensuring long-term stability and minimal losses. Analysts forecast significant gains (29.57% to 79.74%) for top-ten GASV stocks by January 2026, highlighting high-yield, low-risk investment opportunities. |
seekingalpha.com |
2025-01-22 20:16:53 |
Czytaj oryginał (ang.) |
| 4 Of 35 Safe-Buy Dividend Power Dogs In January |
Four low-priced Dividend Power stocks, Golden Ocean, Invesco Mortgage, ARMOUR Residential, and FutureFuel, offer safer dividends with free cash-flow yields exceeding dividend yields. The Dividend Power strategy focuses on high earnings yield and top dividend yield stocks, creating a resilient portfolio for both downturns and bull markets. Analysts project significant gains for top Dividend Power stocks, with an average net gain of 79.97% on $10k invested in the top ten. |
seekingalpha.com |
2025-01-05 10:38:14 |
Czytaj oryginał (ang.) |
| Of 36 Dividend Power Dogs, 11 Are Buyable In November |
Eleven of the 35 Dividend Power Dogs are recommended for their "safer" dividends, with free cash-flow yields exceeding dividend yields, making them ideal buys. The Dividend Power strategy focuses on high earnings yield and high dividend yield, creating a resilient portfolio for both downturns and bull markets. Analysts project significant gains for the top ten DiviPower stocks by November 2025, with potential net gains ranging from 55.4% to 108.51%. |
seekingalpha.com |
2024-11-29 07:51:15 |
Czytaj oryginał (ang.) |
| SITE Centers Announces Tax Estimate for Curbline Properties Distribution |
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Tax Estimate for Curbline Properties Distribution. |
businesswire.com |
2024-11-25 18:05:00 |
Czytaj oryginał (ang.) |
| CBL & Associates Properties Vs. SITE Centers: Which Is The Better REIT For 2025 |
CBL & Associates Properties and SITE Centers are REITs focused on retail real estate, with reported occupancy rates indicating poor competitive dynamics. CBL funds a greater proportion of its capital structure with debt, but both companies have significant floating rate debt exposure. CBL is more attractively valued on an enterprise-level and AFFO multiple basis, but also reports higher administrative expenses. |
seekingalpha.com |
2024-11-13 17:21:08 |
Czytaj oryginał (ang.) |
| HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker |
Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell response, with good overall safety Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell response, with good overall safety |
globenewswire.com |
2024-11-11 18:05:00 |
Czytaj oryginał (ang.) |
| Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME |
Two oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics' TCR-T PRAME franchise to target solid cancers |
globenewswire.com |
2024-11-08 19:00:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting |
Data continues positive trend as additional patients are enrolled in 3 cohorts Vaccine was safe and well tolerated by participants in all 3 cohorts Protocol defined immune responses were exhibited in over 70% of patients A Phase 2 study evaluating the vaccine in the neoadjuvant setting is planned to commence in 2025 SAN JOSE, Calif. , Nov. 8, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of new, updated positive data from the Phase 1 clinical trial of its breast cancer vaccine (NCT04674306) at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held in Houston, Texas. |
prnewswire.com |
2024-11-08 15:17:00 |
Czytaj oryginał (ang.) |
| Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting |
BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation entitled “Pharmacodynamic and Response Biomarkers in the Monotherapy Arm of a Phase 1 Trial of CTX-471, a Novel Anti-CD137 Agonist Antibody” at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, from November 6-10, 2024 in Houston, TX. |
globenewswire.com |
2024-11-08 12:05:00 |
Czytaj oryginał (ang.) |
| Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) |
MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2 SK ) to the tumor microenvironment (TME), where it is conditionally activated by tumor-associated proteases |
globenewswire.com |
2024-11-08 12:00:00 |
Czytaj oryginał (ang.) |
| BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference |
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 08, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today is pleased to report preclinical data showing strong anti-cancer activity of its next generation, personalized, off-the-shelf, cell-based breast and prostate cancer immunotherapies, Bria-BRES+™ and Bria-PROS+™, respectively, during a poster session at the 2024 Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, held November 6-10, 2024, in Houston, TX. |
globenewswire.com |
2024-11-08 09:50:00 |
Czytaj oryginał (ang.) |
| Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024 |
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that new preclinical data supporting the clinical development of its proprietary next generation antibody-drug conjugate (ADC) and innovative tetra-specific ANKET® will be presented at the SITC Annual Meeting 2024. “We are thrilled to share our latest preclinical data at the SITC Annual Meeting, highlighting the potential of IPH6501, our tetra-spe. |
businesswire.com |
2024-11-08 03:00:00 |
Czytaj oryginał (ang.) |
| Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting |
HONG KONG , Nov. 7, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from November 6 - 10, Akeso Biopharma (9926. HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, targeting both Claudin18.2 (CLDN18.2) and CD47. |
prnewswire.com |
2024-11-07 21:20:00 |
Czytaj oryginał (ang.) |
| Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) |
Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed tumor site-specific pharmacodynamic activity and immune activation |
globenewswire.com |
2024-11-07 18:15:00 |
Czytaj oryginał (ang.) |